The collaboration will combine PharmaTher’s ketamine formulation with CCBIO’s Felice Dose wearable delivery device to develop wearable ketamine delivery solutions for mental health, neurological & pain disorders. The collaboration complements PharmaTher’s portfolio including injectable, IV & microneedle patch
PharmaTher’s device aims to convert IV & IM ketamine delivery to SC which can improve safety & efficacy, reduce side effects, improve patient comfort & adherence, reduce time burden & expands the use of ketamine
CCBIO will lead development, clinical manufacturing activities & support PharmaTher’s regulatory submissions. The clinical studies are expected to be initiated in Q1’23 for the wearable ketamine delivery device
Ref: Globenewswire | Image: PharmaTher
